These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 9815886

  • 1. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
    Tortora G, Ciardiello F, Damiano V, Pepe S, Bianco C, di Isernia G, Davies SL, North P, Harris AL, Hickson ID.
    Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
    [Abstract] [Full Text] [Related]

  • 2. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.
    Tagliaferri P, Tortora G, Guarrasi R, Damiano V, Ruggiero A, Morelli D, Caraglia M, Bianco R, di Isernia G, Pepe S, Arteaga CL, Langton-Webster BC, Bianco AR, Ciardiello F.
    Clin Cancer Res; 1996 Jan; 2(1):207-14. PubMed ID: 9816108
    [Abstract] [Full Text] [Related]

  • 3. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS.
    Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
    [Abstract] [Full Text] [Related]

  • 4. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC, Yokozaki H, Saeki T, Elliott JW, Masui H.
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [Abstract] [Full Text] [Related]

  • 5. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Sep; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 6. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES.
    Cancer Res; 1999 Sep 15; 59(18):4618-24. PubMed ID: 10493516
    [Abstract] [Full Text] [Related]

  • 7. Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
    Kim SN, Kim SG, Park SD, Cho-Chung YS, Hong SH.
    J Cell Physiol; 2000 Mar 15; 182(3):421-8. PubMed ID: 10653609
    [Abstract] [Full Text] [Related]

  • 8. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G.
    Int J Cancer; 2000 Mar 01; 85(5):710-5. PubMed ID: 10699953
    [Abstract] [Full Text] [Related]

  • 9. Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells.
    Pepe S, Ruggiero A, Tortora G, Ciardiello F, Garbi C, Yokozaki H, Cho-Chung YS, Clair T, Skalhegg BS, Bianco AR.
    Cytometry; 1994 Jan 01; 15(1):73-9. PubMed ID: 8162827
    [Abstract] [Full Text] [Related]

  • 10. The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor.
    Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, Pelicci PG, Ciardiello F.
    Oncogene; 1997 Feb 27; 14(8):923-8. PubMed ID: 9050991
    [Abstract] [Full Text] [Related]

  • 11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.
    Clin Cancer Res; 2000 Apr 27; 6(4):1488-97. PubMed ID: 10778981
    [Abstract] [Full Text] [Related]

  • 12. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B, Sehested M, Jensen PB.
    Clin Cancer Res; 1998 Jun 27; 4(6):1367-73. PubMed ID: 9626452
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T, Mattern MR, Mirabelli CK, Hanna N.
    Cancer Res; 1990 May 01; 50(9):2636-40. PubMed ID: 2158396
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ, White RL, Matsunami N, Neufeld KL.
    Cancer Res; 2000 Dec 15; 60(24):6989-94. PubMed ID: 11156401
    [Abstract] [Full Text] [Related]

  • 15. Type II protein kinase A up-regulation is sufficient to induce growth inhibition in SK-N-SH human neuroblastoma cells.
    Kim SN, Lee GR, Hwang ES, Lee JH, Park SD, Cho-Chung YS, Hong SH.
    Biochem Biophys Res Commun; 1997 Mar 17; 232(2):469-73. PubMed ID: 9125203
    [Abstract] [Full Text] [Related]

  • 16. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M, Beck WT.
    Cancer Res; 1993 Dec 15; 53(24):5946-53. PubMed ID: 8261408
    [Abstract] [Full Text] [Related]

  • 17. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 18. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
    Wang SJ, Peyrollier K, Bourguignon LY.
    Arch Otolaryngol Head Neck Surg; 2007 Mar 01; 133(3):281-8. PubMed ID: 17372087
    [Abstract] [Full Text] [Related]

  • 19. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H, Ise T, Nomoto M, Kato K, Murakami T, Ohmori H, Imamura T, Nagatani G, Okamoto T, Ohta R, Furukawa M, Shibao K, Izumi H, Kuwano M, Kohno K.
    Anticancer Drug Des; 1999 Apr 01; 14(2):87-92. PubMed ID: 10405635
    [Abstract] [Full Text] [Related]

  • 20. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS, Cho-Chung YS.
    Clin Cancer Res; 2003 Mar 01; 9(3):1171-8. PubMed ID: 12631623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.